Epstein Secrets

fferently. Eye-opening to see how accustomed one can become to the assumptions, whims and rules of VCs. For example, investors starting Helicos took Eric's advice over mine in 2003 (even though he had zero sequencing technology invention experience and I had 26 years) -- so rather than a large founder

m pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs. 6) Making human genetic disease models in organoids and aging reversal using CRISPR

ferently. Eye-opening to sec how accustomed one can become to the assumptions, whims and rules of VCs. For example, investors starting Helicos took Eric's advice over mine in 2003 (even though he had zero sequencing technology invention experience and I had 26 years) -- so rather than a large founder

m pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs. 6) Making human genetic disease models in organoids and aging reversal using CRISPR

[email protected] COWEN WASHINGTON RESEARCH GROUP Eric Assaraf 202 868 5304 [email protected] Any p

e highlight two such agreements from the past few months below. Amyris / Undisclosed Partner (February 2019; Valued Up to $255MM) In February 2019, Amyris announced that it has signed an agreement for cannabinoid development, licensing, and commercialization in a partnership valued at up to $255MM (not